Fingerprint
Dive into the research topics of 'A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically